Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 16% w/w cream for topical use. It treats actinic keratosis and superficial basal cell carcinoma through photodynamic therapy, selectively destroying abnormal skin cells while sparing surrounding tissue.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Metvix is a topical photosensitizer used in photodynamic therapy for precancerous and early skin cancers. - Actinic keratosis: clears precancerous lesions by inducing selective cytotoxicity after red‑light activation, reducing progression to squamous cell carcinoma. - Superficial basal cell carcinoma: eradicates superficial skin cancer cells through targeted photodynamic treatment, offering a non‑surgical alternative for eligible lesions. - Photodynamic therapy of skin lesions: enables controlled destruction of abnormal skin tissue while preserving healthy surrounding skin, suitable for various dysplastic lesions.

The most frequently reported reactions to Metvix are related to local skin response and illumination. Common Side Effects: - Erythema: redness at the application site. - Edema: swelling of the treated area. - Pain or burning sensation during or after illumination. - Crusting or scaling of the skin. - Itching or pruritus. - Hyperemia. Serious or Rare Side Effects: - Severe photosensitivity reactions extending beyond the treated field. - Infection of the treated area requiring medical intervention. - Allergic contact dermatitis. - Persistent ulceration or scarring. - Hyperpigmentation or hypopigmentation. - Systemic phototoxicity in rare cases.

Before using Metvix, healthcare professionals should consider several safety measures to minimize adverse outcomes. - Light exposure: avoid direct sunlight or strong artificial light on treated area for at least 48 hours after illumination. - Application area: limit use to diagnosed lesions and follow prescribed treatment field dimensions. - Patient selection: exercise caution in immunocompromised patients or those with extensive skin disease. - Pregnancy and lactation: safety not established; avoid use unless benefit outweighs potential risk. - Concomitant photosensitizing agents: review patient medications and discontinue or adjust as appropriate. - Store at below 25°C: keep the cream in the original container, protect from moisture and light.

Metvix may interact with other agents that influence photosensitivity or skin healing. Major Interactions (Avoid): - Tetracycline antibiotics (e.g., doxycycline): increase risk of severe photosensitivity. - Oral retinoids (e.g., isotretinoin): enhance skin irritation and phototoxic response. - Phenothiazine antipsychotics (e.g., chlorpromazine): potentiate photosensitivity. - Amiodarone: may cause exaggerated phototoxic reactions. - St. John’s wort: can increase photosensitivity. Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce efficacy of photodynamic treatment if applied immediately after therapy. - Systemic chemotherapy agents: may impair wound healing and increase risk of infection at treatment sites.